Ignite part 4. When to start immunoglobulin replacement therapy for SID

Ignite part 4. When to start immunoglobuling replacement therapy for SID

A detailed investigation of when to initiate immunoglobulin replacement therapy (IgRT) in patients with SID, focusing on guidelines and clinical practices, the role of IgRT in managing haematological malignancies, and the need for multidisciplinary approaches.

The vital role of IgRT in preventing infections

This session focuses on the causes and consequences of secondary immunodeficiency, particularly in the context of haematological malignancies such as CLL and multiple myeloma. It highlights the challenges in early identification and management of SID, alongside impact of IgRT on reducing infection rates and improving patient outcomes.

Emphasising IgRT guidelines and facilitated subcutaneous immunoglobulin therapy efficacy and safety

Presenting a Delphi exercise aimed at reaching a consensus on the use of IgRT to treat SID associated with haematological malignancies, alongside the importance of patient involvement in treatment decisions.